Beta Bionics, Inc. (BBNX)
| Market Cap | 887.20M +7.6% |
| Revenue (ttm) | 119.01M +52.5% |
| Net Income | -72.97M |
| EPS | -1.65 |
| Shares Out | 44.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,640,621 |
| Open | 19.47 |
| Previous Close | 19.54 |
| Day's Range | 19.25 - 20.07 |
| 52-Week Range | 8.80 - 32.71 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 20.31 (+2.99%) |
| Earnings Date | Jul 29, 2026 |
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which co... [Read more]
Financial Performance
In 2025, Beta Bionics's revenue was $100.25 million, an increase of 53.94% compared to the previous year's $65.12 million. Losses were -$73.20 million, 33.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for BBNX stock is "Buy." The 12-month stock price target is $20.31, which is an increase of 2.99% from the latest price.
News
Beta Bionics initiated with a Market Perform at William Blair
William Blair initiated coverage of Beta Bionics (BBNX) with a Market Perform rating. The firm believes Beta has a solid pipeline, led by its expected entry into the patch pump…
Beta Bionics price target raised to $18 from $15.50 at BofA
BofA analyst Travis Steed raised the firm’s price target on Beta Bionics (BBNX) to $18 from $15.50 and keeps a Neutral rating on the shares. The firm raised its multiple…
Beta Bionics price target raised to $15.50 from $13 at BofA
BofA raised the firm’s price target on Beta Bionics (BBNX) to $15.50 from $13 and keeps a Neutral rating on the shares. Following the Q2 report, the firm applies a…
Beta Bionics price target lowered to $30.40 from $32 at Ladenburg
Ladenburg analyst Jeffrey Cohen lowered the firm’s price target on Beta Bionics (BBNX) to $30.40 from $32 and keeps a Buy rating on the shares.
Beta Bionics Earnings Call Transcript: Q2 2026
Q2 2026 saw 38% year-over-year revenue growth to $32M, with gross margin expanding to 59% and strong new patient starts, especially from those switching from multiple daily injections. The company advanced its innovation pipeline, raised gross margin guidance, and remains well-capitalized for future growth.
Beta Bionics Earnings release: Q2 2026
Beta Bionics released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Beta Bionics Slides: Q2 2026
Beta Bionics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Beta Bionics Quarterly report: Q2 2026
Beta Bionics has published its Q2 2026 quarterly earnings report on July 29, 2026.
Beta Bionics reports Q2 EPS (53c), consensus (56c)
Reports Q2 revenue $32.01M, consensus $31.46M. The company said, “New patient starts increased by at least 10% but less than 20% sequentially versus the first quarter of 2026.” Published first…
Beta Bionics backs FY26 revenue view $131M-$136M, consensus $133.48M
Narrows FY26 gross margin view to 58.5%-59.5% from 57.5%-59.5%. Backs FY26 new patient starts reimbursed through the PBP channel view 37%-39%.
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial resu...
Beta Bionics resumed with a Buy at UBS
UBS analyst Patrick Wood resumed coverage of Beta Bionics (BBNX) with a Buy rating with a price target of $22, down from $24, as part of a broader note on…
Beta Bionics price target raised to $19 from $17 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Beta Bionics (BBNX) to $19 from $17 and keeps a Buy rating on the shares.
Beta Bionics price target raised to $22 from $18 at Truist
Truist raised the firm’s price target on Beta Bionics (BBNX) to $22 from $18 and keeps a Buy rating on the shares as part of a broader research note on…
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to ...
Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)
SAN DIEGO--(BUSINESS WIRE)---- $BBNX #BBNX--Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation con...
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
SAN DIEGO, June 12, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concer...
Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors...
Beta Bionics, Inc. (BBNX) Investigation: Johnson Fistel Investigates Investor Losses Following Slower New Patient Start Growth
SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws.
Beta Bionics management to meet with Piper Sandler
Meeting to be held on June 9-11 hosted by Piper Sandler..
Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws
Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws
Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel
SAN DIEGO--(BUSINESS WIRE)---- $bbnx #BBNX--Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The i...
Beta Bionics Investors Who Suffered Losses May Be Eligible for Recovery-Learn More Today, Contact Johnson Fistel
San Diego, California--(Newsfile Corp. - June 2, 2026) - Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securitie...
Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
IRVINE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-ti...
Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders
SAN DIEGO--(BUSINESS WIRE)---- $BBNX #BetaBionicsInc--Shareholder Rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and ...